Recherche
Résultats 11-20 de 29
-
Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study
Lancet Oncology, Elsevier, 2021, 23; 1, 161-171Article dans une revue scientifiquetexte intégral -
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
BMC Cancer, BioMed Central, 29-05-2021, 21; 1, 642Compte-rendu et recension critique d'ouvragetexte intégral -
Modulatory effect of rapamycin and tacrolimus on monocyte-derived dendritic cells phenotype and function
Immunobiology, Elsevier, 2021, 226; 1, 152031Compte-rendu et recension critique d'ouvragetexte intégral -
Microsurgical resection of fronto-temporo-insular gliomas in the non-dominant hemisphere, under general anesthesia using adjunct intraoperative mri and no cortical and subcortical mapping: a series of 20 consecutive patients
Scientific Reports, 26-03-2021, 11, 6994Article dans une revue scientifiquetexte intégral -
Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma.
EClinicalMedicine, 23-05-2021, 35, 100844Compte-rendu et recension critique d'ouvragetexte intégral -
Loss of hepatocyte identity following aberrant YAP activation: a key mechanism in alcoholic hepatitis
Elsevier, 12-06-2021Autre communication scientifique (congrès sans actes - poster - séminaire...)texte intégral -
18f-fdg positron emission tomography scanning in systemic sclerosis-associated interstitial lung disease: a pilot study
Arthritis Research & Therapy, 06-03-2021, 23, 76Article dans une revue scientifiquetexte intégral -
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update
ESMO Open, European Society for Medical Oncology, 10-2021, 6; 5, 100273Compte-rendu et recension critique d'ouvragetexte intégral -
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
The Lancet, Elsevier, 01-2021, 397; 10272, 375-386Compte-rendu et recension critique d'ouvragetexte intégral -
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
The Lancet, Elsevier, 2021, 22; 2, 198-211Compte-rendu et recension critique d'ouvragetexte intégral